Medscape9d
FDA Adds Anaphylaxis Risk Warning to Multiple Sclerosis Drug Glatiramer Acetate
From 1996-2024, 82 cases of anaphylaxis associated with glatiramer acetate were reported to the FDA Adverse Event Reporting ...
The Financial Express7d
USFDA issues warning of serious allergic reaction with multiple sclerosis drugs; Urges patients to be cautious
“For most patients who experienced anaphylaxis with glatiramer acetate use, the symptoms appeared within one hour of injection. In some cases, anaphylaxis resulted in hospitalization and death ...
Healio8d
FDA issues anaphylaxis warning on multiple sclerosis treatment
The FDA has advised health care professionals and patients with multiple sclerosis that treatment with glatiramer acetate is ...
The American Journal of Managed Care8d
FDA Warns of Severe Allergic Reactions With Certain Multiple Sclerosis Drugs
The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment.
Monthly Prescribing Reference7d
FDA: Anaphylaxis Risk Prompts Boxed Warning for MS Drug
Reports of anaphylaxis associated with the use of glatiramer acetate have prompted the Food and Drug Administration (FDA) to add a Boxed Warning to the prescribing information.
FDA Warns Of Severe Allergic Reaction Risk With Teva's Multiple Sclerosis Drug
FDA issues new warnings about rare but severe allergic reactions, including anaphylaxis, linked to MS drug glatiramer acetate, urging immediate medical attention.
MedPage Today9d
FDA Warns About Anaphylaxis Risk With MS Drug
Opens in a new tab or window The FDA added a boxed warning about rare cases of anaphylaxis associated with the multiple sclerosis (MS) drug glatiramer ... within 1 hour of injection and include ...
The Pharma Letter9d
FDA warns of rare but serious allergic reaction with glatiramer
For most patients who experienced anaphylaxis with glatiramer acetate use, the symptoms appeared within one hour of injection. All the news that moves the needle in pharma and biotech Exclusive ...